Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2405)	4/15/2010 10:10:54 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

PPHM was up 9.41% and is still up 7.38% at present with volume of > 360Ks already > its ADV. The stock is up for 4th day on a roll and opened with a small UG.<g> bigcharts.marketwatch.com It announced today the publication of new data highlighting the tumor-killing potential of its lead phosphatidylserine targeting antibody, bavituximab, in combination with an agent that induces apoptosis. The study published in the journal Breast Cancer Research and Treatment, bavituximab combined with an investigational apoptosis-inducing drug produced powerful anti-tumor effects, completely eradicating 30% of tumors in a model of advanced breast cancer. More than half of human breast cancers involve suppression of normal apoptosis. Bavituximab in combination with chemotherapy is in ongoing PII for treatment of advanced breast cancer and non-small cell lung cancer. The ACTAY is $9 and it seems that PPHM could get to test its May2009 H at $5.65 <g> bigcharts.marketwatch.com Although since PPHM has been trimming its losses for the last 4Qs and it was awarded a patent for its phosphatidyserine targeting antibodies in Nov.,with further good news, the $9 ACTAY could be obtainable.<g> bigcharts.marketwatch.com Bernard